Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®

December 16, 2022

https://www.globenewswire.com/news-release/2022/12/16/2575338/0/en/Ocugen-Announces-Phase-3-Confirmatory-Clinical-Trial-Agreement-for-NeoCart.html

MALVERN, Pa., Dec. 16, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the U.S. Food & Drug Administration (FDA) agreed to Ocugen’s proposed control and overall design for the Phase 3 study of NeoCart®, a regenerative cell therapy for the repair of full-thickness lesions of the knee cartilage in adults.

Read more at globenewswire.com

Related news for (OCGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.